

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Kindstar Globalgene Technology, Inc.
康聖環球基因技術有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 9960)

VOLUNTARY ANNOUNCEMENT
APPOINTMENT OF CHIEF SCIENTIFIC OFFICER

This announcement is made by Kindstar Globalgene Technology, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors (the “**Board**”) of the Company is pleased to announce that, Dr. Jian-Bing FAN (“**Dr. FAN**”) has been appointed as the chief scientific officer of the Company, with effect from September 27, 2024. Dr. FAN will be responsible for the R&D innovation and application transformation in specific technological fields. He will provide decision-making support and consulting services for the Company and involve in the cultivation and introduction of technical talent of the Group.

Dr. FAN is the founder of Guangzhou AnchorDx Medical Co., Ltd.* (廣州市基準醫療有限責任公司) (“**AnchorDx**”). Before the establishment of AnchorDx, he served as a senior CTO in Illumina, Inc. (“**Illumina**”). As a core R&D personnel of Illumina’s microarray technology at the early stage, Dr. FAN led the team to successfully develop a series of products, which have been widely used in various key fields including genomics, genotyping, gene expression and DNA methylation. Before joining Illumina, Dr. FAN worked at the then microarray giant, Affymetrix, Inc., where he led the team to develop scientific application products for large-scale genotyping.

Dr. FAN received his doctoral degree in human genetics from Columbia University in the United States. He carried out postdoctoral research at the human genome centers of University of California, San Francisco and Stanford University in the United States and independently led the research teams to conduct the technical work related to genomic research.

The Board would like to express its warm welcome to Dr. FAN.

By Order of the Board
Kindstar Globalgene Technology, Inc.
康聖環球基因技術有限公司
HUANG Shiang
Chairman

Hong Kong, September 27, 2024

As of the date of this announcement, the Board comprises Dr. HUANG Shiang, Mr. TU Zanbing and Ms. CHAI Haijie as executive Directors, Mr. HUANG Zuie-Chin, Mr. PENG Wei and Ms. HUANG Lu as non-executive Directors, and Dr. YAO Shanglong, Dr. XIA Xinping and Mr. GU Huaming as independent non-executive Directors.